Abstract
Adenovirus vectors are the most commonly employed vector for cancer gene therapy. They are also used for gene therapy and as vaccines to express foreign antigens. Adenovirus vectors can be replication-defective; certain essential viral genes are deleted and replaced by a cassette that expresses a foreign therapeutic gene. Such vectors are used for gene therapy, as vaccines, and for cancer therapy. Replication-competent (oncolytic) vectors are employed for cancer gene therapy. Oncolytic vectors are engineered to replicate preferentially in cancer cells and to destroy cancer cells through the natural process of lytic virus replication. Many clinical trials indicate that replication-defective and replication-competent adenovirus vectors are safe and have therapeutic activity.
Keywords: Adenovirus, replication-defective, oncolytic, cancer gene therapy, vaccines, safe and well-tolerated.
Current Gene Therapy
Title:Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
Volume: 13 Issue: 6
Author(s): William S.M. Wold and Karoly Toth
Affiliation:
Keywords: Adenovirus, replication-defective, oncolytic, cancer gene therapy, vaccines, safe and well-tolerated.
Abstract: Adenovirus vectors are the most commonly employed vector for cancer gene therapy. They are also used for gene therapy and as vaccines to express foreign antigens. Adenovirus vectors can be replication-defective; certain essential viral genes are deleted and replaced by a cassette that expresses a foreign therapeutic gene. Such vectors are used for gene therapy, as vaccines, and for cancer therapy. Replication-competent (oncolytic) vectors are employed for cancer gene therapy. Oncolytic vectors are engineered to replicate preferentially in cancer cells and to destroy cancer cells through the natural process of lytic virus replication. Many clinical trials indicate that replication-defective and replication-competent adenovirus vectors are safe and have therapeutic activity.
Export Options
About this article
Cite this article as:
Wold S.M. William and Toth Karoly, Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy, Current Gene Therapy 2013; 13 (6) . https://dx.doi.org/10.2174/1566523213666131125095046
DOI https://dx.doi.org/10.2174/1566523213666131125095046 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets MicroRNAs: Emerging Role in the Endogenous μ Opioid System
CNS & Neurological Disorders - Drug Targets Kernelized Convex Hull based Collaborative Representation for Tumor Classification
Current Proteomics PD-1/PD-Ls: A New Target for Regulating Immunopathogenesis in Central Nervous System Disorders
Current Drug Delivery The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery A Novel Highly Selective Cannabinoid CB2 Agonist Reduces in vitro Growth and TGF-beta Release of Human Glial Cell Tumors
Central Nervous System Agents in Medicinal Chemistry Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Prognostic Role of Hedgehog-GLI1 Signaling Pathway in Aggressive and Metastatic Breast Cancers
Current Drug Metabolism Incorporating Link Information in Feature Selection for Identifying Tumor Biomarkers by Using miRNA-mRNA Paired Expression Data
Current Proteomics Biological Activities of Eco-Friendly Synthesized Hantzsch Adducts
Medicinal Chemistry MR Spectroscopy in Metabolic Profiling Studies of Stem Cells
Current Medical Imaging Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Perspectives of Fullerenes, Dendrimers, and Heterocyclic Compounds Application in Tumor Treatment
Recent Patents on Nanomedicine FK506 Binding Proteins as Targets in Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry